Type 1 Diabetes
Research Study

The POLARIS Study is evaluating a one-time, investigational cell therapy for adults recently diagnosed with type 1 diabetes. This therapy, made from a participant’s own blood cells, is designed to help restore immune balance and slow disease progression. Unlike current treatments, it aims to address the underlying cause of type 1 diabetes, not just manage blood sugar.

Fast Facts

Received a type 1 diabetes diagnosis within the last 6 months

Ages 18-55

Overall in
Good Health

Conducted in
Multiple Locations

Additional Information

The purpose of the POLARIS Study is to evaluate the safety of GNTI-122 and to see whether a single dose of this investigational cell therapy can help preserve remaining insulin-producing cells in adults recently diagnosed with type 1 diabetes.

You may be eligible for this study if you meet the following criteria.

Inclusion Criteria:

  • Diagnosed with type 1 diabetes in the last 6 months
  • Ages 18-55
  • Overall in good health
  • Willing to use contraception


Exclusion Criteria:

  • Other significant or unstable medical conditions
  • Participating in another interventional clinical study
  • Pregnant or breastfeeding

The POLARIS Study is a multi-center clinical trial being conducted at leading research institutions across the United States, including:

  • City of Hope Medical Center – Duarte, CA
  • University of California, San Diego – San Diego, CA
  • University of California, San Francisco – San Francisco, CA
  • University of Florida – Gainesville, FL
  • University of Miami, Diabetes Research Institute – Miami, FL
  • Joslin Diabetes Center – Boston, MA
  • University of North Carolina at Chapel Hill – Chapel Hill, NC
  • Duke University –Durham, NC
  • Columbia University – New York, NY
  • Icahn School of Medicine at Mount Sinai – New York, NY

Additional locations may be added over time.

If you choose to participate, your involvement may include:

  • A phone screening to determine initial eligibility

  • An in-person screening visit, including medical history and lab tests

  • Collection of white blood cells through a procedure called leukapheresis

  • A one-time administration of the investigational therapy (GNTI-122)

  • Follow-up visits at the study site to monitor safety, immune response, and diabetes progression

All study procedures are explained in detail before participation, and you may leave the study at any time.

  •  

Participants will receive compensation for time and travel, which varies by study site and follows industry standards for studies of similar complexity. Parking assistance or transportation support may also be available.

There is no cost for you to participate in our research study.